以上内容基于公开资料整理，不构成投资建议。 股票近期走势 近7个交易日(2026年2月6日至13日)，宣泰医药股价区间下跌1.16%，最高价10.55元，最低价10.14元， 振幅3.95%。截至2月13日最新价10.25元，当日跌0.19%，换手率0.00%。资金流向方面，2月13日主力资 金净流入为0元，成交主要由散户主导。 经济观察网宣泰医药公告其产品熊去氧胆酸胶囊拟中选国家组织集采第1-8批协议期满品种接续采购， 若后续签订合同并实施，有望扩大销售规模和提高市场占有率。同日，公司持股5%以上股东Finer Pharma Inc.计划通过集中竞价或大宗交易减持不超过906.68万股(占总股本2%)，减持原因为股东自身资 金需求，减持期间为2026年3月11日至6月10日。 ...

Group 1 - The company, Shanghai Xuantai Pharmaceutical Technology Co., Ltd., has participated in the national organized procurement for the first to eighth batches of expiring agreements and has been proposed for selection in the continuation procurement for its product, ursodeoxycholic acid capsules [1] - The proposed selection will allow medical institutions to prioritize the use of the selected drug, ensuring the completion of the agreed procurement volume, which is expected to positively impact the company's sales scale, market share, and brand influence [1] Group 2 - The final selection data will be based on the results published by the continuation procurement office [1]

Group 1 - The core point of the article is that Xuantai Pharmaceutical announced its participation in the national organized procurement for drugs whose agreements have expired, specifically regarding the procurement of ursodeoxycholic acid capsules [2] - The company received notification from the procurement office on February 10, 2026, indicating that its product is proposed to be selected in the continuation of the procurement process [2]

Group 1 - *ST Lifan completed the stock price fluctuation verification work and will resume trading on February 11, 2026, with no significant changes in fundamentals but risks of irrational speculation and potential price drop [1] - CITIC Securities announced that its subsidiary, Huaxia Fund, achieved a net profit of 2.396 billion yuan in 2025, with total revenue of 9.626 billion yuan [2] - Changfei Fiber noted that the demand for fiber optic products used in data centers is still a small proportion of global market demand, despite recent market interest [3] Group 2 - Minglida announced the termination of its investment in the Zhaoqing new energy key components intelligent manufacturing project due to global economic uncertainties and market conditions [4] - Baichuan Co. reported a significant price increase in some of its main products but cannot predict the impact on its performance due to price volatility [5] - SMIC reported a net profit of 1.223 billion yuan in Q4 2025, representing a year-on-year increase of 23.2% [6] Group 3 - Runtu Co. indicated that the sustainability of price fluctuations in disperse dyes is uncertain, making it difficult to predict the impact on its performance [7] - Zhongtung High-tech plans to invest 145 million yuan in a new PCB drill needle project to expand market share and secure raw material needs [9] - Dawi Technology clarified that its Zhangbei data center project does not involve computing power leasing, with minimal revenue contribution expected in 2025 [10] Group 4 - Dinggu Jichuang's investment in Hubei Hangju Technology is classified as a financial investment and will not significantly impact its operating performance [11] - Yunjiji Group signed a 1.331 billion yuan EPC contract, which accounts for approximately 86.66% of its audited revenue for 2024 [12] - Hengdian Film's AI short drama business is still in the investment stage and has not generated related revenue yet [13] Group 5 - Jiamei Packaging has experienced a stock price increase of 567.11% since December 17, 2025, and may apply for a trading suspension if prices continue to rise [14] - Daqin Railway reported a freight volume of 31.28 million tons in January, a year-on-year increase of 5% [15] - Ankai Bus produced 761 vehicles in January, reflecting a year-on-year increase of 35.65% [20]

Group 1 - Baichuan Co., Ltd. announced a recent price increase for some of its main products due to market supply and demand factors, but the sustainability of this price fluctuation remains uncertain, making it difficult to predict the impact on the company's performance [1] - Jincheng Co., Ltd. plans to increase its acquisition of CMH Company by an additional 42.50% stake, which will give it a total ownership of 97.5% and ultimate control over CMH [2] - Xinhang New Materials intends to raise no more than 1 billion yuan through a private placement of A-shares, with the funds allocated for projects including high-performance resin production and a composite materials innovation center [3] Group 2 - SMIC reported a sales revenue of $2.489 billion for Q4 2025, a 4.5% increase quarter-on-quarter, with an annual revenue of $9.327 billion, reflecting a 16.2% year-on-year growth [4] - China Railway Construction recently won 10 major projects, each valued over 1.5 billion yuan, totaling 45.142 billion yuan, which represents 4.23% of the company's audited revenue for 2024 [5] - Shenzhen Airport recorded a passenger throughput of 5.8795 million in January 2026, a year-on-year increase of 2.84% [6] Group 3 - China State Construction reported a new contract total of 399.5 billion yuan in January 2026, marking a 1.8% year-on-year increase [7] - Jindi Group's sales amount in January 2026 decreased by 45.78% year-on-year, with a signed area of 78,000 square meters [8] - Changyuan Power achieved a power generation of 3.971 billion kWh in January 2026, a year-on-year increase of 37.81% [9] Group 4 - Senyuan Electric is expected to win a project from the Southern Power Grid valued at 272 million yuan [10] - Chengyi Pharmaceutical's products are set to be selected for the national centralized procurement of expiring varieties [12] - Xinwufeng reported a 10.71% year-on-year decrease in pig sales volume in January 2026 [13] Group 5 - Shengnong Development's sales revenue in January 2026 increased by 40.48% year-on-year, with chicken sales volume rising by 42.79% [14] - Minglida announced the termination of its investment in a key component manufacturing project due to global economic uncertainties [15] - CITIC Securities reported that its subsidiary, Huaxia Fund, achieved a net profit of 2.396 billion yuan in 2025 [16] Group 6 - Pianzaihuang completed the first subject enrollment for its Phase II clinical trial of PZH2107 [17] - Xinzhou Bang reported a 16.56% year-on-year increase in net profit for 2025 [18] - Ankai Bus produced 761 vehicles in January 2026, a year-on-year increase of 35.65% [19] Group 7 - Weilan Bio plans to acquire a 50% stake in Aidimeng Weilan for 47 million yuan [20] - Ningbo Gaofa intends to establish a wholly-owned subsidiary with an investment of no more than 100 million yuan [21] - Shanghai Airport signed a leasing contract worth approximately 585 million yuan with the Shanghai Airport Group [22] Group 8 - Fosun Pharma's subsidiary received acceptance for a drug registration application [23] - Jindai Home's subsidiary invested in acquiring shares in a North American market company [24] - Huatong Co. reported a 1.45% year-on-year decrease in pig sales revenue in January 2026 [25] Group 9 - Yunnan Energy Investment's Nanchong Wind Power Project has been approved with a total installed capacity of 62,500 kW [28] - Youyan Silicon reported a 10.14% year-on-year decrease in net profit for 2025 [29] - Jinpu Titanium announced a temporary shutdown of its Nanjing Titanium White production due to reduced demand [30] Group 10 - Yipin Hong completed the sale of its stake in Arthrosi for a total of $9.5 billion in upfront payments [31] - Liande Co. stated that its gas turbine business currently has limited supply, with minimal impact on overall performance [32] - Tiens Wind Power signed new contracts worth 870 million yuan in the offshore engineering sector [33] Group 11 - Daqin Railway reported a freight volume of 31.28 million tons in January 2026, a year-on-year increase of 5% [34] - ST Mingcheng successfully dismissed all claims from Beijing Fusheng in a recent court ruling [35] - Zhiyang Innovation is planning to acquire control of Lingming Photon and will continue its stock suspension for up to five trading days [36][37] Group 12 - Fulai New Materials accelerated the commercialization of flexible sensors, preparing for mass production of its third-generation electronic skin products [38] - Minhe Co. reported a 36.89% year-on-year decrease in sales of broiler chicks in January 2026 [39] - Ruiang Gene received government subsidies totaling 2 million yuan [40] Group 13 - Huiyu Pharmaceutical's shareholder was forced to reduce holdings by 0.307% due to a court order [41] - Fuyuan Pharmaceutical's subsidiary obtained a drug registration certificate for a new oral solution [42] - Xuantai Pharmaceutical's product is set to be selected for national procurement [43] Group 14 - Chunqiu Electronics completed the cancellation of 9.1369 million repurchased shares [44] - Jinguang Electric won a bid worth approximately 28.8691 million yuan [45] - Hongda Co. plans to invest approximately 71.43 million yuan in a 110kV power transmission project [46] Group 15 - Nanchao Foods reported a 1.99% year-on-year decrease in revenue for January 2026 [47] - Shisheng Intelligent plans to repurchase shares worth between 17.5 million and 35 million yuan [48]

Core Viewpoint - The company Xuantai Pharmaceutical (688247.SH) has announced its participation in the national centralized procurement for the continuation of products whose agreements have expired, with its product ursodeoxycholic acid capsules expected to be selected in this procurement process [1] Group 1: Procurement Participation - The company has submitted an application for the national centralized procurement for the first to eighth batches of products whose agreements have expired [1] - The procurement office released the proposed selection results on February 10, 2026, indicating that the company's product is likely to be selected [1] Group 2: Market Impact - The procurement process prioritizes the use of selected drugs by medical institutions, ensuring the completion of the agreed purchase volume [1] - If the company signs procurement contracts and implements them, it will help expand the sales scale of its products, increase market share, and enhance brand influence [1] - This development is expected to have a positive impact on the company's future operating performance [1]

Core Viewpoint - XuanTai Pharmaceutical (688247.SH) has participated in the national centralized procurement for the continuation of products from the first to eighth batches, with its product, ursodeoxycholic acid capsules, being proposed for selection in the continuation procurement process [1] Group 1: Procurement Participation - The company has submitted an application for the continuation procurement of products whose agreements have expired, as announced by the continuation procurement office on February 10, 2026 [1] - The proposed selection of the company's product indicates a potential for increased sales and market share [1] Group 2: Impact on Business - If the company signs procurement contracts and implements them, it will likely enhance the sales scale and brand influence, positively affecting future operational performance [1]

Core Viewpoint - Xuantai Pharmaceutical (688247.SH) has announced its participation in the national organized procurement for the continuation of products whose agreements have expired, with its product, ursodeoxycholic acid capsules, being proposed for selection in this procurement process [1] Group 1: Procurement Participation - The company is involved in the national organized procurement for the first to eighth batches of products whose agreements have expired [1] - The procurement office released the proposed selection results on February 10, 2026, indicating that the company's product is likely to be selected [1] Group 2: Impact on Business - If the company signs procurement contracts and implements them, it will help expand the sales scale of its products [1] - The selection is expected to increase the company's market share and enhance brand influence, positively impacting future operating performance [1]

Core Viewpoint - The announcement indicates that the approval for the marketing authorization holder of Ursodeoxycholic Acid Capsules has been transferred from Hunan Chunjian Pharmaceutical Technology Co., Ltd. to Changle Pharmaceutical, a subsidiary of Lianhuan Pharmaceutical [1] Company Summary - Lianhuan Pharmaceutical's subsidiary, Changle Pharmaceutical, has received approval from the National Medical Products Administration for the marketing authorization of Ursodeoxycholic Acid Capsules [1] - The approval signifies a strategic shift in the ownership of the marketing rights for the drug, which may impact the company's market positioning and revenue potential [1]

Company Announcements - Tongfu Microelectronics reported a net profit growth of 95.08% in Q3, with revenue of 7.08 billion yuan, up 17.94% year-on-year [1] - Guizhou Moutai's chairman Zhang Deqin resigned, with Chen Hua recommended as the new chairman [3] - Victory Shares is planning to acquire gas-related assets controlled by its major shareholder, leading to a stock suspension [3] - Northern Rare Earth's net profit increased by 280% in the first three quarters, driven by higher sales volume [5] - China Nuclear Engineering signed contracts for the construction of the Haiyang Nuclear Power Units 5 and 6 [5] - Kingsoft Office's net profit grew by 35.42% in Q3, with WPS 365 revenue increasing by 71.61% [6] - Postal Savings Bank received approval to establish a financial asset investment company with a registered capital of 10 billion yuan [8] - West Mining's subsidiary won exploration rights for a copper polymetallic mine for 8.609 billion yuan [4] Financial Performance - High德红外 reported a net profit increase of 1059% in Q3, with revenue of 1.134 billion yuan, up 71.07% year-on-year [17] - Purtai's net profit grew by 69% in Q3, supported by strong demand in the power and energy storage battery markets [18] - Yubo Technology's net profit surged by 384% in the first three quarters, driven by rapid growth in AIDC market orders [14] - Sichuan Gold's net profit increased by 184% in Q3, attributed to rising gold prices [16] - Hailey Wind Power's net profit skyrocketed by 779% in Q3, with revenue up 134.73% [7] - Huazhi Technology's net profit rose by 51% in Q3, mainly due to business expansion [5] Strategic Investments - Zhenyu Technology plans to invest 2.11 billion yuan in humanoid robot precision module and component projects [9] - China Aluminum's subsidiary plans to invest 500 million yuan in Yunnan Aluminum Foil [20] - Zhongfu Industrial intends to invest 356 million yuan in a new energy aluminum foil project [19] - Kaishan Group signed contracts for an 800 million USD green ammonia project in Kenya [19]